Table 1

Clinical characteristics and effects of intensive glucose lowering vs. standard therapy on primary CV end point, total mortality, and CV mortality in ACCORD, ADVANCE, and VADT

ACCORDADVANCEVADT
n10,25111,1401,791
Age (years)626660
Men/women (%)61/3958/4297/3
Duration of study (years)3.55.05.6
BMI (kg/m2)32.2 ± 5.528.0 ± 5.031.3 ± 3.5
Duration of diabetes (years)10811.5
CVD35%32%40%
Primary CVD end point↓10% (P = 0.16)↓6% (P = 0.37)↓13% (P = 0.12)
Mortality (overall)↑22% (P = 0.04)↓7% (P = NS)↑6.5% (P = NS)
CV mortality↑35% (P = 0.02)↓12% (P = NS)↑25% (P = NS)